Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response

“…8–7 . 9) c 2,886 (27) 51 67 100% ≥F3; 74% F4orDC GT1 68% HIV coinfected cohorts Limketkai 2012 [ 47 ] United States (prospective) IFN-α or Peg-IFN + RBV 5.2 212 (17) 46 (41–50) 66 42% ≥F2 GT1 91%; non-GT1 9% Berenguer 2012 [ 12 ] Spain (retrospective-prospective) IFN-α or Peg-IFN + RBV 5.0 1599 (39) 40 (37–43) 75 39% F3/F4 GT1 49%; non-GT1 51% P-Gonzalez 2013 [ 48 ] Brazil (retrospective) Peg-IFN + RBV 2.0 42 (33) 44 (29–67) 78 48% F4 GT1 54%; non-GT1 46% Mira 2013 [ 49 ] Spain (prospective) Peg-IFN + RBV 4.6 166 (26) 43 (39–48) 86 100% F4 GT1 58%; non-GT1 42% Labarga 2014 [ 50 ] Spain (retrospective) Peg-IFN + RBV 6.1 339 (41) 41 78 40% F3/F4 GT1or4 73% Overall (5 studies) 5 . 0 (IQR 4 .…”

Hepatitis C

“…Current believe is that if the patient succeed to drop the viral load more than or equal to 2 log or became HCV RNA negative at 12 th week of therapy, may clinically be taken under consideration to short the therapy duration 11 . It has also been recently suggested that the therapy duration may be reduced in the patients who became HCV RNA negative at 4 th week of the treatment 12,13 . The Interferon therapy is not only costly but has its well-known adverse side effects; therefore, the prediction of treatment response is very important to characterize the responders and non responders at the early stages.…”